Semin Thromb Hemost 2022; 48(01): 008-014
DOI: 10.1055/s-0041-1736168
Review Article

Cerebral Venous Thrombosis Developing after COVID-19 Vaccination: VITT, VATT, TTS, and More

1   Section of Clinical Biochemistry, University of Verona, Verona, Italy
2   Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), NSW Health Pathology, Westmead Hospital, Westmead, New South Wales, Australia
3   School of Biomedical Sciences, Charles Sturt University, Wagga Wagga, New South Wales, Australia
› Author Affiliations
Funding None.


Despite the huge efforts globally underway for preventing or limiting the spread of severe acute respiratory coronavirus disease 2 (SARS-CoV-2), the coronavirus disease 2019 (COVID-19) pandemic outbreak appears still virtually unstoppable. As for many other infectious diseases, COVID-19 vaccination has now become crucial for limiting viral spread, especially for averting hospitalizations, need for intensive care, and fatal outcome. Nonetheless, as for other vaccines, COVID-19 vaccination is not completely free from side effects. Among the adverse events that have been reported after receiving COVID-19 vaccination, special emphasis has been given to an unexpected number of thrombocytopenic episodes with or without thrombotic complications, especially in recipients of adenovirus-based COVID-19 vaccines. Along with a specific clinical presentation, encompassing “atypical” thrombosis (especially cerebral venous [sinus] thrombosis, CVT) more prevalent in young female subjects, this new syndrome called vaccine-induced thrombocytopenia and thrombosis (VITT) is characterized by, and thereby diagnosed for, the presence of three paradigmatic laboratory abnormalities, i.e., low platelet count (<150 × 109/L), elevated plasma D-dimer levels (>0.5 mg/L), accompanied by a positive test for anti-PF4 (platelet factor 4) antibodies assayed with ELISA (enzyme-linked immunosorbent assay) techniques. Timely identification of these important abnormalities by both clinicians and laboratory professional is essential for early diagnosis and management of VITT, since the outcome of this condition may be fatal in half or even more of effected patients with severe disease. Therefore, this narrative review aims to review here the epidemiology, pathogenesis, clinical, and laboratory characteristics of VITT and other COVID-19 vaccine-associated thrombocytopenias.


The opinions expressed in this review are those of the authors and do not necessarily represent the views of the University of Verona, Charles Sturt University, or NSW Health Pathology.

Publication History

Article published online:
25 October 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

  • References

  • 1 Toor J, Echeverria-Londono S, Li X. et al. Lives saved with vaccination for 10 pathogens across 112 countries in a pre-COVID-19 world. eLife 2021; 10: e67635
  • 2 Evans SJW, Jewell NP. Vaccine effectiveness studies in the field. N Engl J Med 2021; 385 (07) 650-651
  • 3 Novak N, Tordesillas L, Cabanillas B. Adverse rare events to vaccines for COVID-19: from hypersensitivity reactions to thrombosis and thrombocytopenia. Int Rev Immunol 2021; (e-pub ahead of print) DOI: 10.1080/08830185.2021.1939696.
  • 4 Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med 2021; 384 (22) 2092-2101
  • 5 Schultz NH, Sørvoll IH, Michelsen AE. et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med 2021; 384 (22) 2124-2130
  • 6 Favaloro EJ. Laboratory testing for suspected COVID-19 vaccine-induced (immune) thrombotic thrombocytopenia. Int J Lab Hematol 2021; 43 (04) 559-570
  • 7 Lavin M, Elder PT, O'Keeffe D. et al. Vaccine-induced immune thrombotic thrombocytopenia (VITT) - a novel clinico-pathological entity with heterogeneous clinical presentations. Br J Haematol 2021; (e-pub ahead of print) DOI: 10.1111/bjh.17613.
  • 8 Lardinois B, Favresse J, Chatelain B, Lippi G, Mullier F. Pseudothrombocytopenia—a review on causes, occurrence and clinical implications. J Clin Med 2021; 10 (04) 594
  • 9 Hunter PR. Thrombosis after COVID-19 vaccination. BMJ 2021; 373 (958) n958
  • 10 Pomara C, Sessa F, Ciaccio M. et al. Post-mortem findings in vaccine-induced thrombotic thombocytopenia. Haematologica 2021; 106 (08) 2291-2293
  • 11 Althaus K, Möller P, Uzun G. et al. Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia. Haematologica 2021; 106 (08) 2170-2179
  • 12 Simpson CR, Shi T, Vasileiou E. et al. First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland. Nat Med 2021; 27 (07) 1290-1297
  • 13 Cari L, Fiore P, Naghavi Alhosseini M, Sava G, Nocentini G. Blood clots and bleeding events following BNT162b2 and ChAdOx1 nCoV-19 vaccine: an analysis of European data. J Autoimmun 2021; 122: 102685
  • 14 Schulz JB, Berlit P, Diener HC. et al; DGN SARS-CoV-2 Vaccination Study Group. COVID-19 vaccine-associated cerebral venous thrombosis in Germany. Ann Neurol 2021; (e-pub ahead of print) DOI: 10.1002/ana.26172.
  • 15 Lee EJ, Cines DB, Gernsheimer T. et al. Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. Am J Hematol 2021; 96 (05) 534-537
  • 16 Bikdeli B, Chatterjee S, Arora S. et al. Cerebral venous sinus thrombosis in the U.S. population, after adenovirus-based SARS-CoV-2 vaccination, and after COVID-19. J Am Coll Cardiol 2021; 78 (04) 408-411
  • 17 Hwang J, Lee SB, Lee SW. et al. Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines. J Autoimmun 2021; 122: 102681
  • 18 Krzywicka K, Heldner MR, Sánchez van Kammen M. et al. Post-SARS-CoV-2-vaccination cerebral venous sinus thrombosis: an analysis of cases notified to the European Medicines Agency. Eur J Neurol 2021; (e-pub ahead of print) DOI: 10.1111/ene.15029.
  • 19 Elalamy I, Gerotziafas G, Alamowitch S. et al; Scientific Reviewer Committee. SARS-CoV-2 Vaccine and Thrombosis: An Expert Consensus on Vaccine-Induced Immune Thrombotic Thrombocytopenia. Thromb Haemost 2021; 121 (08) 982-991
  • 20 Ulivi L, Squitieri M, Cohen H, Cowley P, Werring DJ. Cerebral venous thrombosis: a practical guide. Pract Neurol 2020; 20 (05) 356-367
  • 21 See I, Su JR, Lale A. et al. US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination, March 2 to April 21, 2021. JAMA 2021; 325 (24) 2448-2456
  • 22 Goldman M, Hermans C. Thrombotic thrombocytopenia associated with COVID-19 infection or vaccination: possible paths to platelet factor 4 autoimmunity. PLoS Med 2021; 18 (05) e1003648
  • 23 Watanabe Y, Mendonça L, Allen ER. et al. Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine. ACS Cent Sci 2021; 7 (04) 594-602
  • 24 Ogata AF, Cheng CA, Desjardins M. et al. Circulating SARS-CoV-2 vaccine antigen detected in the plasma of mRNA-1273 vaccine recipients. Clin Infect Dis 2021; (e-pub ahead of print) DOI: 10.1093/cid/ciab465.
  • 25 Huynh A, Kelton JG, Arnold DM, Daka M, Nazy I. Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia. Nature 2021; 596 (7873): 565-569
  • 26 Kowarz E, Krutzke L, Reis J, Bracharz S, Kochanek S, Marschalek R. “Vaccine-induced Covid-19 mimicry” syndrome: splice reactions within the SARS-CoV-2 spike open reading frame result in spike protein variants that may cause thromboembolic events in patients immunized with vector-based vaccines. Res Sq 2021; (e-pub ahead of print) DOI: 10.21203/
  • 27 Greinacher A, Selleng K, Mayerle J. et al. Anti-platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein. Blood 2021; 138 (14) 1269-1277
  • 28 Rzymski P, Perek B, Flisiak R. Thrombotic thrombocytopenia after COVID-19 vaccination: in search of the underlying mechanism. Vaccines (Basel) 2021; 9 (06) 559
  • 29 Terpos E, Politou M, Ntanasis-Stathopoulos I. et al. High prevalence of anti-PF4 antibodies following ChAdOx1 nCov-19 (AZD1222) vaccination even in the absence of thrombotic events. Vaccines (Basel) 2021; 9 (07) 712
  • 30 Maayan H, Kirgner I, Gutwein O. et al. Acquired thrombotic thrombocytopenic purpura: a rare disease associated with BNT162b2 vaccine. J Thromb Haemost 2021; (e-pub ahead of print) DOI: 10.1111/jth.15420.
  • 31 Platton S, Bartlett A, MacCallum P. et al. Evaluation of laboratory assays for anti-platelet factor 4 antibodies after ChAdOx1 nCOV-19 vaccination. J Thromb Haemost 2021; 19 (08) 2007-2013
  • 32 Reilly-Stitt C, Kitchen S, Jennings I. et al. Anti-PF4 testing for vaccine-induced immune thrombocytopenia and thrombosis and heparin induced thrombocytopenia: results from a UK National External Quality Assessment Scheme exercise April 2021. J Thromb Haemost 2021; (e-pub ahead of print) DOI: 10.1111/jth.15423.
  • 33 Vayne C, Rollin J, Gruel Y. et al. PF4 immunoassays in vaccine-induced thrombotic thrombocytopenia. N Engl J Med 2021; 385 (04) 376-378
  • 34 Makris M, Pavord S, Lester W, Scully M, Hunt B. Vaccine-induced immune thrombocytopenia and thrombosis (VITT). Res Pract Thromb Haemost 2021; 5 (05) e12529
  • 35 Koupenova M, Corkrey HA, Vitseva O. et al. SARS-CoV-2 initiates programmed cell death in platelets. Circ Res 2021; (e-pub ahead of print) DOI: 10.1161/CIRCRESAHA.121.319117.
  • 36 Limami Y, Khalki L, Zaid N. et al. Oxford-AstraZeneca ChAdOx1 COVID-19 vaccine does not alter platelet aggregation. Semin Thromb Hemost 2021; (e-pub ahead of print) DOI: 10.1055/s-0041-1728831.
  • 37 Vinholt PJ, Frederiksen H, Nielsen C. Modeling the effects of intravasal administration of AstraZeneca ChAdOx1 nCoV-19 vaccine on human platelets. Thromb Haemost 2021; 121 (12) 1681-1683
  • 38 Nazy I, Sachs UJ, Arnold DM. et al. Recommendations for the clinical and laboratory diagnosis of VITT against COVID-19: Communication from the ISTH SSC Subcommittee on Platelet Immunology. J Thromb Haemost 2021; 19 (06) 1585-1588